Welcome to Derma Topics

Welcome to DermaTopics.dk a site maintaied soly with the purpos on securing availability and ease of use of tool and knowledge for other dermatology medical specialists. SO, please, if you are not a dermatology medical specialist use the information we provide with great caution – it is simply meant to support other specialist and will under no circumstance provide sufficient information for any one to draw any medical or treament wise decisions/conclusions.

SALT Score

The severity of Alopecia Areata (AA) is typically measured with the Severity of ALopecia Tool (SALT) Score1,2 .  The SALT Score is computed by measuring the percentage of hair loss in each of the 4 areas of the scalp — the right profile (accounting for 18% of the total scalp area), the left profile (18%), the vertex (40%), and the posterior (24%), see also figure 4 below. By adding the total procentage of hair loss for each region multiplied by the regions relative area, one achieves a composite total score ie the SALT Score. Hair regrowth is reflected by a decrease in the SALT score (eg, complete hair regrowth would confer a SALT score of 0). Below you will find a simple tool that does the SALT SCORE calculation based on hair loss in each of the above mentioned regions.

Definition of the four main scalp areas associated with the SALT Score. A) Right profile region, B) Left profile, C) Vertex region and D) Posterior region. Image copyright: Kirsten Rønholt
Figure 1: Definition of the four main scalp areas associated with the SALT Score.
Image copyright: Kirsten Rønholt site author

References: 

1: Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines–part ii. National alopecia areata foundation. J Am Acad Dermatol. 2004;51:440–447

2: Olsen EA, Roberts J, Sperling L, Tosti A, Shapiro J, McMichael A, Bergfeld W, Callender V, Mirmirani P, Washenik K, Whiting D, Cotsarelis G, Hordinsky M. Objective outcome measures: Collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018 Sep;79(3):470-478.e3

ClinRO-score

ClinRO (Clinician-Reported Outcomes):

Used by dermatologists to assess visible changes in eyebrows and eyelashes.

Alopecia areata affects more than just scalp hair. Loss of eyebrows or eyelashes can significantly impact appearance, function, and quality of life. A reliable scoring method is essential— especially when evaluating new treatments.
In 2020, an international research team developed a new scoring method1 that makes it easier and more accurate to assess eyebrows and eyelashes in alopecia areata. Until now, most assessment methods focused mainly on scalp hair loss, leaving important aspects of the disease under-measured.


ClinRO Measure for Eyebrow Hair Loss™ 

Examine both eyebrows from two feet away and select the best response below:

ClinRO Measure for Eyelash Hair Loss™ 

Examine the upper and lower eyelashes of both eyes and select the best response option below:

  1. The eyelashes form a continuous line along the eyelids on both eyes
  2. There are minimal gaps and the eyelashes are evenly spaced along the eyelids on both eyes
  3. There are significant gaps along the eyelids or the eyelashes are not evenly spaced along the eyelids
  4. No notable eyelashes

Reference:

Kathleen W Wyrwich, Helen Kitchen, et al. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. Am J Clin Dermatol. 2020;21(5):725-732. 

DLQI

Dermatology Life Quality Index (DLQI)

The Dermatology Life Quality Index (DLQI) measures the health-related quality of life of adult patients with a skin disease. Below you will find the questionnaire in an in an easy to use online-form format. Following full completion of the form, the tool will calculate the resulting DLQI.

About the author

The author of this page is dermatoligist Kirsten Rønholt from Denmark. This page will be updated only as needed – in the meantime please consult my/our linkedIn profile Kirsten Rønholt.